Tests glofitamab alone and with chemotherapy in young people with relapsed B-cell lymphoma
Tests glofitamab, alone or with chemoimmunotherapy, in children and young adults with returned lymphoma.
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Seoul, South KoreaSee the 2 sitesAlso in 12 other countries, 28 sites
- Trial code
- Registry title
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 65 people, planned
- Started
- 16 Nov 2022
- Expected to end
- 30 Nov 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- Obinutuzumab
- Glofitamab
- Rituximab
- Ifosfamide
- Carboplatin
- Etoposide
- Tocilizumab
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults whose aggressive mature B-cell non-Hodgkin lymphoma came back or did not respond to earlier treatment.
- Age
- From 6 months to under 18 years for Cohort A Part 1 and Cohort B. From 6 months to under 30 years for Cohort A Part 2.
- Sex
- All sexes can join.
- Disease stage
- Aggressive mature B-cell non-Hodgkin lymphoma with CD20, including BL, BAL, DLBCL and PMBCL, that came back or did not respond to treatment. It must be measurable on scans or in the bone marrow.
- Earlier treatment
- Cohort A: first-line standard chemoimmunotherapy did not work or could not be tolerated. Cohort B: at least two earlier chemoimmunotherapy regimens, with no established therapies left. No earlier glofitamab.
- Biomarker or test result
- The lymphoma must express CD20. Tests for hepatitis B and hepatitis C must be negative. The HIV test must be negative, or HIV must be stable on treatment with set blood-test conditions.
Main reasons for not taking part
- Lymphoma only in the brain or spinal cord, or primary CNS lymphoma
- Earlier solid organ transplant
- Active autoimmune disease that needs treatment
- Active infection not cleared before Day 1 of Cycle 1
- Serious allergic reaction to antibody therapy
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Age 6 months to < 18 years at the time of signing Informed Consent for Cohort A Part 1 and Cohort B of the study, and age 6 months to < 30 years old at the time of signing Informed Consent for Cohort A Part 2 of the study
- Histologically re-confirmed diagnosis, via tissue biopsy, or bone marrow aspirate, pleural effusion, or ascites, prior to study entry of aggressive mature B-NHL that expresses CD20 (reconfirmed by IHC or flow cytometry if IHC is not possible), including BL, BAL (mature B-cell leukemia FAB L3), DLBCL, and PMBCL, at the time of first R/R disease for Cohort A and second or greater R/R disease for Cohort B
- Refractory or relapsed disease (i.e., prior treatment was ineffective or intolerable) following first-line standard-of-care chemoimmunotherapy for Cohort A and following at least two prior systemic chemoimmunotherapy regimens and who have exhausted all available established therapies for Cohort B
- Measurable disease, defined as: At least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension; or percentage of bone marrow involvement with lymphoma cells defined by cytomorphological analysis of bone marrow aspirates
- Adequate performance status, as assessed according to the Lansky or Karnofsky Performance Status scales: Participants < 16 years old: Lansky Performance Status ≥ 50%; Participants ≥ 16 years old: Karnofsky Performance Status ≥ 50%
- Adequate bone marrow, liver, and renal function
- Negative test results for acute or chronic hepatitis B virus (HBV), hepatitis C virus (HCV)
- Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count ≥200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
- Negative SARS-CoV-2 antigen or PCR test within 7 days prior to enrollment
- Participants and/or caregivers who are willing and able to complete clinical outcome assessments throughout the study using either paper or interviewer methods
Who cannot take part
- Receipt of glofitamab prior to study enrollment
- Ongoing adverse events from prior anti-cancer therapy that were not resolved to Grade ≤ 1 (exceptions: alopecia, Grade 2 peripheral neuropathy)
- Grade ≥ 3 adverse events, with the exception of Grade 3 endocrinopathy managed with replacement therapy
- Participants with active infections which are not resolved prior to Day 1 of Cycle 1
- Prior solid organ transplantation
- Evidence of significant and uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
- Major surgery or significant traumatic injury < 28 days prior to the obinutuzumab pretreatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
- Administration of a live, attenuated vaccine within 4 weeks before the start of study treatment (obinutuzumab pretreatment) or at any time during the study treatment period and within 12 months after end of study treatment
- Isolated CNS disease of mature B-NHL without systemic involvement, and primary CNS lymphoma
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH), or chronic active Epstein-Barr viral infection (CAEBV)
- Active autoimmune disease requiring treatment
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products, except if the participant was able to safely receive it after initial administration (consider consultation with Medical Monitor)
- History of confirmed progressive multifocal leukoencephalopathy
- Current or past history of uncontrolled non-malignant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Participants with any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- What type of cancer has the patient been diagnosed with?
- Is this cancer newly diagnosed, or has it come back or not responded to treatment?
Where in South Korea
Also in 12 other countries, 28 sites
- Asan Medical CenterSeoul, South KoreaTaking people
- Seoul National University Hospital- Pediatric SiteSeoul, South KoreaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
The 2 groups in the trial
- Arm ATreatment being tested
Participants will receive glofitamab + R-ICE chemoimmunotherapy for up to 3 cycles (cycle length = 21 days).
Treatment: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, and Tocilizumab
- Arm BTreatment being tested
Participants will receive glofitamab monotherapy for up to 12 cycles (cycle length = 21 days).
Treatment: Obinutuzumab, Glofitamab, and Tocilizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Plain-language title
- Tests glofitamab alone and with chemotherapy in young people with relapsed B-cell lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05533775, who can take part
- Record updated
- 5 November 2026